Cobuzzi Robert Joseph Jr. 4
4 · Diffusion Pharmaceuticals Inc. · Filed Apr 19, 2022
Insider Transaction Report
Form 4
Cobuzzi Robert Joseph Jr.
Chief Operating Officer
Transactions
- Conversion
Series C Convertible Preferred Stock
2022-04-18$25.00/sh−100$2,500→ 0 totalExercise: $25.00→ Common Stock (100 underlying) - Conversion
Common Stock
2022-04-18$25.00/sh+100$2,500→ 792 total
Footnotes (2)
- [F1]As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation.
- [F2]All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022.